Amylyx Pharmaceuticals, Inc.
AMLX
$9.26
$0.839.85%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.42% | 4.37% | 48.36% | -0.01% | 38.80% |
| Total Depreciation and Amortization | -9.62% | -2.50% | -27.60% | 6.25% | -33.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 18.73% | 0.96% | -87.76% | 184.18% | -87.60% |
| Change in Net Operating Assets | 208.26% | 65.54% | -151.99% | -21.87% | -5,401.83% |
| Cash from Operations | 36.60% | 32.51% | -41.95% | 37.56% | -13,515.54% |
| Capital Expenditure | -54.55% | 45.00% | 99.94% | -40,556.18% | -32.84% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 152.72% | -167.15% | -13.33% | 359.77% | -3,358.69% |
| Cash from Investing | 152.67% | -167.19% | 67.41% | 234.03% | -3,636.14% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -92.58% | 555.41% | -69.86% | 944.68% | -96.75% |
| Repurchase of Common Stock | 88.36% | -2,228.95% | 90.75% | -1,955.00% | 98.48% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.05% | 59,592.73% | 37.50% | 196.30% | -79.39% |
| Foreign Exchange rate Adjustments | 208.63% | 137.52% | -322.46% | 705.13% | 64.55% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 90.48% | -417.15% | 327.93% | 97.45% | -27,323.08% |